<SEC-DOCUMENT>0001178913-25-004151.txt : 20251231
<SEC-HEADER>0001178913-25-004151.hdr.sgml : 20251231
<ACCEPTANCE-DATETIME>20251231131315
ACCESSION NUMBER:		0001178913-25-004151
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250209
FILED AS OF DATE:		20251231
DATE AS OF CHANGE:		20251231

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Abramov Dror Yosef
		CENTRAL INDEX KEY:			0002034083
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42253
		FILM NUMBER:		251616782

	MAIL ADDRESS:	
		STREET 1:		13 ZAMENHOF STREET
		CITY:			HERZLIYA
		STATE:			L3
		ZIP:			4659213

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silexion Therapeutics Corp
		CENTRAL INDEX KEY:			0002022416
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		12 ABBA HILLEL ROAD
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5250606
		BUSINESS PHONE:		972-8-6286005

	MAIL ADDRESS:	
		STREET 1:		12 ABBA HILLEL ROAD
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5250606

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Biomotion Sciences
		DATE OF NAME CHANGE:	20240506
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>zk2534153.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-02-09</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0002022416</issuerCik>
        <issuerName>Silexion Therapeutics Corp</issuerName>
        <issuerTradingSymbol>SLXN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002034083</rptOwnerCik>
            <rptOwnerName>Abramov Dror Yosef</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>13 ZAMENHOF STREET</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>HERZLIYA</rptOwnerCity>
            <rptOwnerState>L3</rptOwnerState>
            <rptOwnerZipCode>4659213</rptOwnerZipCode>
            <rptOwnerStateDescription>ISRAEL</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2025-02-09</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>794</value>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>794</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Ordinary Shares</value>
                <footnoteId id="F3"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>295</value>
                    <footnoteId id="F4"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy ordinary shares)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>18.90</value>
                <footnoteId id="F5"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-02-09</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>935</value>
                    <footnoteId id="F5"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2026-02-09</value>
            </exerciseDate>
            <expirationDate>
                <value>2035-02-09</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>935</value>
                    <footnoteId id="F5"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>935</value>
                    <footnoteId id="F5"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Represents ordinary shares underlying RSUs granted to the Reporting Person by the Issuer. The shares subject to this award vest in full on the first anniversary of the date of grant, subject to the Reporting Person's continued service through such date.</footnote>
        <footnote id="F2">The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.</footnote>
        <footnote id="F3">There were no transactions effected in respect of the ordinary shares reported in this row, and the holdings in this row are being included for informational purposes only.</footnote>
        <footnote id="F4">The number of ordinary shares reported in this row has been adjusted downwards to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.</footnote>
        <footnote id="F5">The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Mirit Horenshtein Hadar, Attorney-in-fact</signatureName>
        <signatureDate>2025-12-31</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24.1
<SEQUENCE>2
<FILENAME>exhibit_24-1.htm
<DESCRIPTION>EXHIBIT 24.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: zk-global
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u> </u>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u><br>
        Exhibit 24.1</u></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">POWER OF ATTORNEY</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Know all by these presents, that the undersigned hereby constitutes and appoints Mirit Horenshtein Hadar, chief
      financial officer of Silexion Therapeutics Corp (formerly known as Biomotion Sciences) (the &#8220;Company&#8221;), with full power of substitution, signing individually, the undersigned&#8217;s true and lawful attorney-in fact and agent to:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">1. Prepare, execute in the undersigned&#8217;s name and on the undersigned&#8217;s behalf, and submit to the Securities and
      Exchange Commission (the &#8220;SEC&#8221;) Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) of the Exchange Act and the rules and regulations thereunder in the undersigned&#8217;s
      capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">3. Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to execute
      such Forms 3, 4, or 5, (including any amendments thereto) and timely file such forms with the SEC, and any stock exchange, self-regulatory association or similar authority; and</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">4. Take any other action of any nature whatsoever in connection with the foregoing that, in the opinion of such
      attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be
      in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact&#8217;s discretion.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every
      act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of
      substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact&#8217;s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers
      herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, and his substitutes, in serving in such capacity at the request of the undersigned, is not assuming (nor is the Company assuming) any of the undersigned&#8217;s
      responsibilities to comply with Section 16 of the Exchange Act.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no
      longer required to file Forms 3, 4 and 5 with respect to the undersigned&#8217;s holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (c) as
      to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 15th day of August,
      2024.</div>
    <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1ab389554ff345699ebb150955ab382d" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 2.28%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.46%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 91.26%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Dror J. Abramov</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.28%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 6.46%; vertical-align: top;">
            <div style="line-height: 1.25;">Name:</div>
          </td>
          <td style="width: 91.26%; vertical-align: top;">
            <div style="line-height: 1.25;">Dror J. Abramov</div>
          </td>
        </tr>
        <tr>
          <td style="width: 2.28%; vertical-align: top;">&#160;</td>
          <td style="width: 6.46%; vertical-align: top;">
            <div style="line-height: 1.25;">Date:</div>
          </td>
          <td style="width: 91.26%; vertical-align: top;">
            <div style="line-height: 1.25;">August 15, 2024</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="line-height: 1.25;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
